Tolerability of paliperidone: A meta-analysis of randomized, controlled trials

International Clinical Psychopharmacology

Volumn 25, Issue 6, 2010, Pages 334-341

  Harrington, Catherine A ^a   English, Clayton ^b  

^a NOVA SOUTHEASTERN UNIVERSITY   (United States)

^b ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

adverse drug reactions; attributable risk; meta analysis paliperidone; tolerabiltiy

Indexed keywords

BENZATROPINE; PALIPERIDONE; PLACEBO;

ABDOMINAL PAIN; AKATHISIA; AMENORRHEA; ANORGASMIA; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONSTIPATION; DIZZINESS; DRUG EFFICACY; DRUG TOLERABILITY; DYSARTHRIA; DYSKINESIA; DYSPEPSIA; DYSTONIA; ELECTROCARDIOGRAM; EXTRAPYRAMIDAL SYMPTOM; GYNECOMASTIA; HEADACHE; HUMAN; HYPERKINESIA; HYPERSALIVATION; IMPOTENCE; INSOMNIA; LACTATION; LIBIDO DISORDER; LIPID BLOOD LEVEL; META ANALYSIS; MUSCLE HYPERTONIA; MUSCULOSKELETAL PAIN; ORTHOSTATIC HYPOTENSION; PARKINSONISM; PRIORITY JOURNAL; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; SYSTEMATIC REVIEW; TACHYCARDIA; TREMOR; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT GAIN; XEROSTOMIA;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; FEMALE; HUMANS; ISOXAZOLES; MALE; PSYCHOTIC DISORDERS; PYRIMIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA;

EID: 77958494719     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/YIC.0b013e32833db3d8     Document Type: Article

References (27)

1. Canuso CM, Dirks B, Carothers J, Kosik-Gonzalez C, Bossie CA, Zhu Y, et al. (2009a). Randomized, double-blind, placebo-controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophrenia. Am J Psychiatry 166:691-701.
2. Canuso CM, Schooler N, Kosik-Gonzalez C, Lindermayer JP, Turkoz I, Carothers J, Bossie CA (2009b). 'A Randomized, Double Blind, Placebo-Controlled Study of Flexible Dose Paliperidone ER in the Treatment of Patients with Schizoaffective Disorder' Presented at the 12th International Congress on Schizophrenia Research in San Diego, CA, April (See also clinical study report synopsis, Johnson & Johnson Pharmaceutical Research & Development LLC, NCT00412373, accessed from www.clinicaltrials.gov on 1/29/ 2010).
3. Canuso CM, Lindenmayer J-P, Kosik-Gonzalez C (2009c). 'A Randomized, Double-Blind, Placebo-Controlled Study of Paliperidone ER in the Treatment of Subjections with Schizoaffective Disorder' Presented at the US Pscyhiatric and Mental Health Congress in San Diego, CA, November (See also clinical study report synopsis, Kwentus J, R076477-SCA-3001, Ortho-McNeil Janssen Scientific Affairs, LLC, NCT00397033, accessed from www. clinicaltrials.gov on 1/29/2010).
4. Cutler A (2007). A randomized, double-blind, placebo-controlled, parallel-group, dose-response, multicenter study to evaluate the efficacy and safety of three fixed doses of extended-release paliperidone in the treatment of subjects with acute manic or mixed episodes associated with Bipolar I disorder. Johnson & Johnson Pharmaceutical Research and Development LLC, accessed from www.clinicaltrials.gov on 1/29/2010.
5. Davidson M, Emsley R, Kramer M, Ford L, Pan G, Lim P, Eerdekens M (2007). Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr Res 93:117-130. (Pubitemid 46817944)
6. Edwards SJ, Smith CJ (2009). Tolerability of atypical antipsychotics in the treatment of adults with schizophrenia or bipolar disorder: a mixed treatment comparison of randomized controlled trials. Clin Ther 31:1345-1359.
7. Emsley R, Berwaerts J, Eerdekens M, Kramer M, Lane R, Lim P, et al. (2008). Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies. Int Clin Psychopharmacol 23:343-356.
8. Haddad PM, Wieck A (2004). Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 64:2291-2314.
9. Johnson & Johnson Pharmaceutical Research & Development, LLC (2009). A study of the efficacy and safety of one dosage of paliperidone extended release in treating patients with schizophrenia. NCT00524043. Accessed from www.clinicaltrials.gov on 3/1/2010.
10. Kane J, Canas F, Kramer M, Ford L, Gassmann-Mayer C, Lim P, Eerdekens M (2007). Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res 90:147-161.
11. Kapur S, Zipursky R, Jones C, Remington C, Houle S (2000). Relationship between dopamine (D2) occupancy, clinical response, and side effects: a double blind PET study of first-episode schizophrenia. Am J Psychiatry 157:514-520.
12. Knegtering R, Baselmans P, Castelein S, Bosker F, Bruggeman R, van den Bosch RJ (2005). Predominant role for the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels. Am J Psychiatry 162:1010-1012.
13. Kramer M, Simpson G,Maciulis V, Kushner S, Vijapurkar U, Lim P, Eerdekens M (2007). Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 27:6-14. (Pubitemid 46105757)
14. Luthringer R, Staner L, Noel N, Muzet M, Gassmann-Mayer C, Talluri K, et al. (2007). A double-blind, placebo-controlled, randomized study evaluating the effect of paliperidone extended-release tablets on sleep architecture in patients with schizophrenia. Int Clin Psychopharmacol 22:299-308.
15. Marino J, Cabellero J (2008). Paliperidone extended-release for the treatment of schizophrenia. Pharmacotherapy 28:1283-1298.
16. Marder S, Kramer M, Ford L, Eerdekens E, Lim P, Eerdekens M, Lowy A (2007). Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biol Psychiatry 62:1363-1370.
17. Melkersson KI (2006). Prolactin elevation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite. Hum Psychopharmacol Clin Exp 21:529-532.
18. Meltzer HY, Bobo WV, Nuamah IF, Lane R, Hough D, Kramer M, et al. (2008). Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies. J Clin Psychiatry 69:817-829.
19. Newcomer JW (2005). Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 19 (Suppl 1):1-93.
20. Nussbaum AM, Stroup TS (2008). Oral paliperidone for schizophrenia. Cochrane Database of Systematic Reviews 66-86. (Issue 2. Art. No.: CD006369).
21. Odawara T (2007). A Placebo-Controlled Double-Blind Comparative Study of JNS007ER in Patients with Schizophrenia, Janssen Pharmaceutical K.K. (Accessed from www.clinicaltrials.gov on 1/29/2010).
22. Ortho-McNeil-Janssen Pharmaceuticals, Inc. (2007). Invega (paliperidone extended-release) prescription information, Revised: July 2009 10105906
23. Reisenberg R (2007). A randomized, double-blind, placebo-controlled, parallel-group, dose-response, multicenter study to evaluate the efficacy and safety of flexibly-dosed extended-release paliperidone as adjunctive therapy to mood stabilizers in treatment of acute manic or mixed episodes associated with Bipolar I disorder, Johnson & Johnson Pharmaceutical Research and Development LLC, accessed from www.clinicaltrials.gov on 1/29/2010.
24. Review Manager (RevMan) (2008). [Computer program]. Version 5. 0 Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, accessed from www.cc-ims.net/revman
25. Schotte A, Bonaventure P, Janssen P, Leysen JE (1995). In vitro receptor binding and in vivo receptor occupancy in rat and guinea pig brain: risperidone compared with antipsychotics hitherto used. Jpn J Pharmaco 69:399-412.
26. Tzimos A, Samokhvalov V, Kramer M, Ford L, Gassmann-Mayer C, Lim P, Eerdekens M (2008). Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension. Am J Geriatric Psychiatry 16:31-43.
27. Yang LPH, Plosker GL (2007). Paliperidone extended release. CNS Drugs 21:417-425.